Results 101 to 110 of about 16,336,802 (316)

Association Between Neurofilament Light Chain and Real‐World Ambulatory Function in Progressive MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurofilament light chain (NfL) is a biomarker of neuroaxonal injury in multiple sclerosis (MS), yet associations with functional outcomes remain unclear. Longitudinal associations between serum NfL (sNfL) and daily step count (STEPS) from wearable devices were assessed in a large international progressive MS cohort.
Gabby B. Joseph, Megan McCune, Riley Bove, Ahmed Abdelhak, Bruce A. C. Cree, Valerie J. Block   +5 more
wiley   +1 more source

Safety Profile of Opicapone in the Management of Parkinson’s Disease

Journal of Parkinson’s Disease, 2019
Background: Opicapone is a catechol O-methyltransferase (COMT) inhibitor indicated for use as adjunct to levodopa therapy in patients with Parkinson’s disease (PD) and motor fluctuations.
Andrew Lees, Joaquim J. Ferreira, José-Francisco Rocha, Olivier Rascol, Werner Poewe, Helena Gama, Patrício Soares-da-Silva   +6 more
doaj   +1 more source

Conditioning open-label placebo: a pilot pharmacobehavioral approach for opioid dose reduction and pain control

PAIN Reports, 2020
Introduction:. Opioid consumption for those in comprehensive inpatient rehabilitation units is high because of the complexity of their injuries. Notably, pain in rehabilitation leads to worsened clinical outcomes because of maladaptive behaviors and poor
Leon Morales-Quezada, Ines Mesia-Toledo, Anayali Estudillo-Guerra, Kevin C. O'Connor, Jeffrey C. Schneider, Douglas J. Sohn, David M. Crandell, Ted Kaptchuk, Ross Zafonte   +8 more
doaj   +1 more source

Placebo effect of an inert gel on experimentally induced leg muscle pain. [PDF]

, 2010
Purpose: This study examined the therapeutic effects of an inert placebo gel on experimentally induced muscle pain in a sports therapy setting. It aimed to investigate the degree to which conditioned analgesia, coupled with an expectation of intervention,
Coleman, Damian A, Beedie, C., Leach, G., Foad, A., Hopker, James G.   +4 more
core   +1 more source

Safety of Prescription Nonsteroidal Anti‐inflammatory Drugs in Adults With Inflammatory Bowel Disease: Data From a Large Administrative Claims Cohort

Arthritis Care &Research, EarlyView.
Objective The concern that nonsteroidal anti‐inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing musculoskeletal symptoms in those with IBD, but safety data are mixed. Methods This retrospective cohort study included patients with IBD aged at least 18 years from Optum's deidentified ...
Adam S. Mayer, Rui Xiao, Meenakshi Bewtra, Michael D. George, Pamela F. Weiss   +4 more
wiley   +1 more source

Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease

BMC Gastroenterology, 2023
Background Short-term efficacy and safety of brazikumab (MEDI2070), a human monoclonal antibody and anti-p19 subunit inhibitor of interleukin-23, was demonstrated in a phase 2a trial in patients with moderate-to-severe active Crohn’s disease (CD).
Silvio Danese, Andrew Beaton, Elizabeth A. Duncan, Anne-Kristina Mercier, Jessica Neisen, Henrik Seth, Sofia Zetterstrand, Bruce E. Sands   +7 more
doaj   +1 more source

Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.

Journal of Allergy and Clinical Immunology: In Practice, 2019
BACKGROUND Cholinergic urticaria (UCOL) is a highly disabling inducible urticaria triggered by an increase in core body temperature. OBJECTIVE To explore the safety and efficacy of omalizumab in controlling UCOL.
G. Gastaminza, J. Azofra, J. Núñez-Córdoba, M. Baeza, S. Echechipía, P. Gaig, B. García, M. Labrador-Horrillo, A. Sala-Cunill, M. Brescó, A. Beristain, D. Quiñones, C. Donado, J. Zubeldia, M. Ferrer   +14 more
semanticscholar   +1 more source

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

Arthritis Care &Research, EarlyView.
Objective Vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS) syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures.
Kevin Byram, Heřman Mann, Danielle Hammond, Onima Chowdhury, Sinisa Savic, Yohei Kirino, Carmelo Gurnari, Maël Heiblig, Thibault Comont, Arsène Mekinian, Mrinal M. Patnaik, Lachelle D. Weeks, Gary Ho, Adam Al‐Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin‐Lavialle, Peter C. Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Raman Garcha, David B. Beck, Matthew J. Koster   +25 more
wiley   +1 more source

Early start of opicapone in Parkinson’s disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations

Frontiers in Neurology
BackgroundLevodopa is the mainstay of Parkinson’s disease (PD) therapy, but its long-term use is often complicated by the development of motor fluctuations.
Joaquim J. Ferreira, Joaquim J. Ferreira, Fabrizio Stocchi, Fabrizio Stocchi, Angelo Antonini, Angelo Antonini, Olivier Rascol, Olivier Rascol, Georg Ebersbach, Jaime Kulisevsky, Jaime Kulisevsky, Jaime Kulisevsky, Miguel M. Fonseca, Daniel Ramos, José Francisco Rocha, Helena C. Brigas, Joerg Holenz, Werner Poewe   +17 more
doaj   +1 more source

Open-label placebo treatment of women with premenstrual syndrome: study protocol of a randomised controlled trial

BMJ Open, 2020
Introduction Recent evidence suggests that for certain clinical conditions, placebos can improve clinical outcomes even without deception. These so-called open-label placebos (OLPs) bear the advantage of a significant lower risk of adverse events and ...
Antje Frey Nascimento, J. Gaab, I. Kirsch, Joe Kossowsky, A. Meyer, C. Locher   +5 more
semanticscholar   +1 more source